Enzyme Inhibition Mechanisms
Explore how drugs block enzyme activity to alter biochemical pathways.
## Introduction
Enzyme inhibitors block or reduce enzymatic activity, preventing the conversion of substrates to products. This class accounts for roughly 47% of all approved drugs, making enzyme inhibition the most common drug mechanism. Enzymes are attractive targets because their active sites provide well-defined binding pockets for rational drug design.
## Types of Enzyme Inhibition
### Competitive Inhibition
The inhibitor competes with the substrate for the active site. Because binding is mutually exclusive, increasing substrate concentration can overcome the inhibition. Kinetically, Km (apparent) increases while Vmax remains unchanged. On a Lineweaver-Burk plot, lines intersect on the y-axis. Example: statins competing with HMG-CoA for HMG-CoA reductase, achieving nanomolar potency.
### Non-Competitive Inhibition
The inhibitor binds an allosteric site distinct from the active site, reducing catalytic activity regardless of substrate concentration. The enzyme-substrate complex still forms but cannot proceed to product. Vmax decreases while Km stays the same. Cannot be overcome by excess substrate, making this mechanism pharmacologically persistent.
### Uncompetitive Inhibition
The inhibitor binds only the enzyme-substrate complex, not the free enzyme. Both Km and Vmax decrease proportionally, so Vmax/Km ratio remains constant. This is rare in single-substrate reactions but more common in multi-substrate enzyme systems and is exploited in drug design for phosphatases.
## Reversible vs Irreversible
Reversible inhibitors bind through non-covalent interactions and dissociate over time, with the inhibition constant Ki quantifying binding affinity. Irreversible inhibitors form covalent bonds with the enzyme, permanently inactivating it. Recovery requires new enzyme synthesis, which may take hours to days. Aspirin irreversibly acetylates COX-1 at Ser530, which is why its antiplatelet effect lasts the lifetime of the platelet (7–10 days).
## Clinical Examples
- **ACE inhibitors** (lisinopril): Block angiotensin-converting enzyme for hypertension
- **Statins** (atorvastatin): Competitive HMG-CoA reductase inhibitors lowering cholesterol
- **MAO inhibitors** (selegiline): Inhibit monoamine oxidase for Parkinson's disease
- **Proton pump inhibitors** (omeprazole): Irreversibly inhibit gastric H+/K+-ATPase
## Key Takeaways
- Enzyme inhibitors are the largest class of drug targets (~47% of approved drugs)
- Competitive inhibitors can be overcome by excess substrate; non-competitive cannot
- Irreversible inhibitors require new enzyme synthesis for recovery
- Inhibition kinetics (changes in Km and Vmax) define the mechanism type